Table 2

Study characteristics by final cognitive diagnosis for individuals with NCI or MCI at baseline

NCI (N=212)MCI (N=160)AD (N=178)Other dementia (N=9)
Gender
 Female148 (69.8%)100 (62.5%)133 (74.7%)5 (55.6%)
 Male64 (30.2%)60 (37.5%)45 (25.3%)4 (44.4%)
Education (years)
 Mean (SD)15.5 (3.6)15.5 (3.1)15.3 (3.2)16.0 (3.8)
 Median (min, max)16.0 (7.0, 27.0)16.0 (5.0, 25.0)16.0 (8.0, 28.0)16.0 (12.0, 24.0)
Age at diagnosis
 Mean (SD)88.8 (6.1)84.0 (5.9)
 Median (min, max)88.9 (71.4, 106)84.4 (74.6, 91.7)
 Missing12 (6.7%)3 (33.3%)
Age at death
 Mean (SD)88.1 (6.5)89.8 (5.9)91.8 (5.7)86.9 (5.9)
 Median (min, max)88.5 (71.3, 103)90.2 (72.1, 104)92.3 (76.0, 106)85.9 (77.3, 95.9)
APOE genotype
E23 43 (20.3%)14 (8.8%)20 (11.2%)2 (22.2%)
E33 143 (67.5%)114 (71.3%)115 (64.6%)3 (33.3%)
E34 26 (12.3%)32 (20.0%)43 (24.2%)4 (44.4%)
Global AD pathology score
 Mean (SD)0.5 (0.5)0.7 (0.6)0.9 (0.6)0.7 (0.4)
 Median (min, max)0.3(0, 2.6)0.6(0.0, 2.3)0.8(0.0, 2.8)0.8(0.0, 1.4)
Beta-amyloid score
 Mean (SD)3.4 (4.0)4.7 (4.6)6.5 (4.8)7.4 (6.9)
 Median (min, max)1.5(0, 22.9)3.5(0, 17.9)6.0(0, 19.9)8.4(0.0, 17.0)
 Missing2 (0.9%)0 (0%)0 (0%)0 (0%)
Neurofibrillary tangle score
 Mean (SD)3.5 (4.0)5.6 (5.9)9.3 (8.5)2.6 (1.9)
 Median (min, max)2.6 (0.0, 27.3)4.1 (0.0, 38.2)6.9 (0.0, 42.8)2.5 (0.5, 5.9)
 Missing2 (0.9%)0 (0%)1 (0.6%)0 (0%)
Modified CERAD
 Definite AD37 (17.5%)44 (27.5%)74 (41.6%)2 (22.2%)
 Probable AD62 (29.2%)64 (40.0%)79 (44.4%)5 (55.6%)
 Possible AD26 (12.3%)17 (10.6%)6 (3.4%)0 (0%)
 No AD87 (41.0%)35 (21.9%)19 (10.7%)2 (22.2%)
Braak stage
 0–II49 (23.1%)27 (16.9%)13 (7.3%)0 (0%)
 III–IV147 (69.3%)99 (61.9%)90 (50.6%)9 (100%)
 V–VI16 (7.5%)34 (21.3%)75 (42.1%)0 (0%)
Cerebral amyloid angiopathy
 066 (31.1%)39 (24.4%)31 (17.4%)3 (33.3%)
 196 (45.3%)74 (46.3%)79 (44.4%)4 (44.4%)
 233 (15.6%)33 (20.6%)47 (26.4%)1 (11.1%)
 316 (7.5%)14 (8.8%)21 (11.8%)1 (11.1%)
 Missing1 (0.5%)0 (0%)0 (0%)0 (0%)
Cerebral atherosclerosis stage
 066 (31.1%)43 (26.9%)27 (15.2%)1 (11.1%)
 196 (45.3%)72 (45.0%)86 (48.3%)2 (22.2%)
 238 (17.9%)36 (22.5%)50 (28.1%)5 (55.6%)
 312 (5.7%)9 (5.6%)15 (8.4%)1 (11.1%)
Gross cerebral infarctions
 Not present132 (62.3%)96 (60.0%)86 (48.3%)3 (33.3%)
 Present80 (37.7%)64 (40.0%)92 (51.7%)6 (66.7%)
Hippocampal sclerosis
 Not present208 (98.1%)155 (96.9%)151 (84.8%)8 (88.9%)
 Present4 (1.9%)5 (3.1%)27 (15.2%)1 (11.1%)
Lewy bodies
 Not present173 (81.6%)124 (77.5%)115 (64.6%)5 (55.6%)
 Present34 (16.0%)29 (18.1%)56 (31.5%)4 (44.4%)
 Missing5 (2.4%)7 (4.4%)7 (3.9%)0 (0%)
Microinfarcts
 Not present134 (63.2%)105 (65.6%)105 (59.0%)5 (55.6%)
 Present78 (36.8%)55 (34.4%)73 (41.0%)4 (44.4%)
TDP-43 staging
 0125 (59.0%)81 (50.6%)65 (36.5%)6 (66.7%)
 146 (21.7%)33 (20.6%)29 (16.3%)2 (22.2%)
 229 (13.7%)31 (19.4%)46 (25.8%)1 (11.1%)
 37 (3.3%)14 (8.8%)38 (21.3%)0 (0%)
 Missing5 (2.4%)1 (0.6%)0 (0%)0 (0%)
HDL-C (mmol/L)
 Mean (SD)1.47 (0.442)1.48 (0.462)1.46 (0.418)1.18 (0.270)
 Median (Min, Max)1.40 (0.518, 2.88)1.42 (0.674, 2.67)1.40 (0.725, 3.73)1.30 (0.725, 1.50)
LDL-C (mmol/L)
 Mean (SD)2.65 (0.833)2.73 (0.850)2.80 (0.871)2.99 (0.972)
 Median (min, max)2.59 (0.648, 4.87)2.66 (1.06, 6.06)2.73 (0.933, 5.41)3.01 (1.37, 4.77)
TG (mmol/L)
 Mean (SD)1.67 (0.800)1.58 (0.774)1.56 (0.755)1.88 (0.700)
 Median (min, max)1.51 (0.542, 4.22)1.37 (0.440, 4.28)1.37 (0.474, 4.28)1.91 (0.926, 3.09)
Lipid lowering treatment
 Not present130 (61.3%)108 (67.5%)118 (66.3%)8 (88.9%)
 Present82 (38.7%)52 (32.5%)60 (33.7%)1 (11.1%)
  • AD, Alzheimer’s disease; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; HDL-C, high-density lipoprotein cholesterol; MCI, mild cognitive impairment; NCI, no cognitive impairment; TG, triglycerides.